Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 9/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | MMP15 | P51511 | 1/20 | 0.42 |
| ▸ | MMP16 | P51512 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067303 | 0.93 | GHSR (0.46) | GHSRPTGDR2MMP2MMP9MMP12 | |
| SCHEMBL3075407 | 0.92 | GHSR (0.45) | GHSRPTGDR2HTR2AACACB | |
| SCHEMBL3078212 | 0.92 | GHSR (0.45) | GHSRHTR2AMMP2MMP9MMP14 | |
| SCHEMBL3074334 | 0.91 | GHSR (0.47) | GHSRPTGDR2 | |
| SCHEMBL3072628 | 0.91 | GHSR (0.51) | GHSRNR4A2 | |
| SCHEMBL3069230 | 0.89 | GHSR (0.54) | GHSRACACB | |
| SCHEMBL3068014 | 0.88 | GHSR (0.48) | GHSRACACB | |
| SCHEMBL3072406 | 0.87 | GHSR (0.55) | GHSR | |
| SCHEMBL3066014 | 0.87 | GHSR (0.52) | GHSRACACB | |
| SCHEMBL3077215 | 0.87 | GHSR (0.50) | GHSRACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951675-B1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-03-20 | — | — | EP | disclosed |
| US-7790745-B2 | Tetrahydroisoquinoline LXR Modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | NR1H2, NR1H3, NR1I2 | GHSR 351/4885NR4A2 25/4885NR4A1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.